In addition, it is worth noting that 5-FU treatment stimulates VEGF-mediated angiogenesis23,24, so a drug can inactivate the aberrant activation of NF-κB/STAT3 and VEGF would possibly overcome chemoresistance and potentiate the efficacy of 5-FU in CRC. The gene discussed is VEGFA; the disease is colorectal carcinoma.